Jul 08, 2021 8:00am EDT Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection
Jul 01, 2021 4:39pm EDT Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021
Apr 29, 2021 8:00am EDT Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
Feb 18, 2021 7:30am EST Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer
Dec 31, 2020 8:00am EST Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Secures $60 Million Capital Commitment From Global Emerging Markets
Sep 28, 2020 8:00am EDT COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment
Sep 08, 2020 8:00am EDT Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Announces Steven R. Martin to Join Board of Directors